Alvotech (ALVO) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mesoblast (MESO) has outperformed Alvotech (ALVO) over the past year, losing 30.4% versus a loss of 34.7%. Alvotech is the larger company by market cap ($2.05 billion vs $1.84 billion), about 1.1 times the size, while Mesoblast is growing revenue faster (+191.4% vs +19.7%). On valuation, Alvotech trades at a lower forward P/E (25.1x vs 31.2x for Mesoblast).
Alvotech converts more of its revenue into profit, with a net margin of 4.8% versus -593.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | MESO |
|---|---|---|
| Share price | $5.74 | $14.20 |
| Market cap | $2.05B | $1.84B |
| 1-day change | +1.23% | +3.27% |
| YTD return | +10.53% | -23.78% |
| 1-year return | -34.68% | -30.38% |
| 5-year return | — | +21.04% |
| Forward P/E | 25.14 | 31.21 |
| EPS (TTM) | $-0.62 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | $17.20M |
| Revenue growth (YoY) | +19.74% | +191.39% |
| Net income (latest FY) | $27.92M | $-102.14M |
| Gross margin | 59.82% | 70.17% |
| Operating margin | 13.34% | — |
| Net margin | 4.76% | -593.92% |
| 52-week high | $9.05 | $21.50 |
| 52-week low | $2.94 | $13.05 |
| Distance from 52-week high | -36.54% | -33.95% |
| Analyst consensus | none | buy |
| Avg. price target upside | +18.47% | +160.56% |
| Average volume | 1.05M | 232.77K |
| Shares outstanding | 356.82M | 129.85M |
| Employees | 1,279 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alvotech is more profitable, keeping 4.8 cents of every revenue dollar as net income versus -593.9 cents for Mesoblast.
- Mesoblast grew revenue faster in its latest fiscal year (+191.39% vs +19.74%).
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
ALVO vs MESO FAQ
Which is bigger, Alvotech or Mesoblast?
Alvotech (ALVO) is larger, with a market capitalization of $2.05B compared with $1.84B for Mesoblast (MESO).
Which stock has performed better over the past year, ALVO or MESO?
MESO returned -30.38% over the past 12 months, compared with -34.68% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Mesoblast in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.